Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million
Aachen (ots) - Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal's investigational medicine Resiniferatoxin ("RTX"). Shionogi obtained the exclusive rights to commercialise Grünenthal's asset in Japan for pain associated with osteoarthritis of the knee. RTX ...
more